FDA's Arthritis Drugs Advisory Committee recommends Celebrex approval

The FDA's Arthritis Drugs Advisory Committee has voted to recommend approval of Pfizer's Celebrex for use in juvenile rheumatoid arthritis, despite long-term safety concerns. They recommended that, if approved, Pfizer continues to study long-term safety and establish a patient registry.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions